ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global VEGFR-2 Inhibitor Market Research Report 2024
Published Date: August 2024
|
Report Code: QYRE-Auto-15M18110
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global VEGFR 2 Inhibitor Market Research Report 2024
BUY CHAPTERS

Global VEGFR-2 Inhibitor Market Research Report 2024

Code: QYRE-Auto-15M18110
Report
August 2024
Pages:79
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Bayer
Pfizer Inc
Jiangsu Hengrui Pharmaceuticals
Chia Tai Tianqing
Novartis
Astrazeneca plc
Exelixis Inc
Boehringer Ingelheim
Eisai Co Ltd

VEGFR-2 Inhibitor Market

A VEGFR-2 inhibitor is a pharmaceutical compound designed to selectively block the vascular endothelial growth factor receptor 2(VEGFR-2).By targeting VEGFR-2,these inhibitors disrupt the signaling pathways that promote the growth of new blood vessels from existing ones.This mechanism is particularly relevant in treating conditions where abnormal angiogenesis plays a detrimental role,such as in certain cancers and retinal diseases.
The global VEGFR-2 Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for VEGFR-2 Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for VEGFR-2 Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of VEGFR-2 Inhibitor include Bayer, Pfizer, Jiangsu Hengrui Pharmaceuticals, Chia Tai Tianqing, Novartis, AstraZeneca, Exelixis, Boehringer Ingelheim, Eisai, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for VEGFR-2 Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding VEGFR-2 Inhibitor.
The VEGFR-2 Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global VEGFR-2 Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the VEGFR-2 Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of VEGFR-2 Inhibitor Market Report

Report Metric Details
Report Name VEGFR-2 Inhibitor Market
Segment by Type
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Bayer, Pfizer, Jiangsu Hengrui Pharmaceuticals, Chia Tai Tianqing, Novartis, AstraZeneca, Exelixis, Boehringer Ingelheim, Eisai
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of VEGFR-2 Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of VEGFR-2 Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the VEGFR-2 Inhibitor Market report?

Ans: The main players in the VEGFR-2 Inhibitor Market are Bayer, Pfizer, Jiangsu Hengrui Pharmaceuticals, Chia Tai Tianqing, Novartis, AstraZeneca, Exelixis, Boehringer Ingelheim, Eisai

What are the Application segmentation covered in the VEGFR-2 Inhibitor Market report?

Ans: The Applications covered in the VEGFR-2 Inhibitor Market report are Cancer Therapy, Ophthalmic Diseases, Other

What are the Type segmentation covered in the VEGFR-2 Inhibitor Market report?

Ans: The Types covered in the VEGFR-2 Inhibitor Market report are Sorafenib, Sunitinib, Lenvatinib, Vandetanib, Cabozantinib, Nintedanib, Apatinib, Other

Recommended Reports

Angiogenesis Inhibitors

Targeted Cancer Drugs

Ophthalmic Treatments

1 VEGFR-2 Inhibitor Market Overview
1.1 Product Definition
1.2 VEGFR-2 Inhibitor by Type
1.2.1 Global VEGFR-2 Inhibitor Market Value Comparison by Type (2024-2030)
1.2.2 Sorafenib
1.2.3 Sunitinib
1.2.4 Lenvatinib
1.2.5 Vandetanib
1.2.6 Cabozantinib
1.2.7 Nintedanib
1.2.8 Apatinib
1.2.9 Other
1.3 VEGFR-2 Inhibitor by Application
1.3.1 Global VEGFR-2 Inhibitor Market Value by Application (2024-2030)
1.3.2 Cancer Therapy
1.3.3 Ophthalmic Diseases
1.3.4 Other
1.4 Global VEGFR-2 Inhibitor Market Size Estimates and Forecasts
1.4.1 Global VEGFR-2 Inhibitor Revenue 2019-2030
1.4.2 Global VEGFR-2 Inhibitor Sales 2019-2030
1.4.3 Global VEGFR-2 Inhibitor Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 VEGFR-2 Inhibitor Market Competition by Manufacturers
2.1 Global VEGFR-2 Inhibitor Sales Market Share by Manufacturers (2019-2024)
2.2 Global VEGFR-2 Inhibitor Revenue Market Share by Manufacturers (2019-2024)
2.3 Global VEGFR-2 Inhibitor Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of VEGFR-2 Inhibitor, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of VEGFR-2 Inhibitor, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of VEGFR-2 Inhibitor, Product Type & Application
2.7 Global Key Manufacturers of VEGFR-2 Inhibitor, Date of Enter into This Industry
2.8 Global VEGFR-2 Inhibitor Market Competitive Situation and Trends
2.8.1 Global VEGFR-2 Inhibitor Market Concentration Rate
2.8.2 The Global 5 and 10 Largest VEGFR-2 Inhibitor Players Market Share by Revenue
2.8.3 Global VEGFR-2 Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global VEGFR-2 Inhibitor Market Scenario by Region
3.1 Global VEGFR-2 Inhibitor Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global VEGFR-2 Inhibitor Sales by Region: 2019-2030
3.2.1 Global VEGFR-2 Inhibitor Sales by Region: 2019-2024
3.2.2 Global VEGFR-2 Inhibitor Sales by Region: 2025-2030
3.3 Global VEGFR-2 Inhibitor Revenue by Region: 2019-2030
3.3.1 Global VEGFR-2 Inhibitor Revenue by Region: 2019-2024
3.3.2 Global VEGFR-2 Inhibitor Revenue by Region: 2025-2030
3.4 North America VEGFR-2 Inhibitor Market Facts & Figures by Country
3.4.1 North America VEGFR-2 Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America VEGFR-2 Inhibitor Sales by Country (2019-2030)
3.4.3 North America VEGFR-2 Inhibitor Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe VEGFR-2 Inhibitor Market Facts & Figures by Country
3.5.1 Europe VEGFR-2 Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe VEGFR-2 Inhibitor Sales by Country (2019-2030)
3.5.3 Europe VEGFR-2 Inhibitor Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific VEGFR-2 Inhibitor Market Facts & Figures by Region
3.6.1 Asia Pacific VEGFR-2 Inhibitor Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific VEGFR-2 Inhibitor Sales by Region (2019-2030)
3.6.3 Asia Pacific VEGFR-2 Inhibitor Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America VEGFR-2 Inhibitor Market Facts & Figures by Country
3.7.1 Latin America VEGFR-2 Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America VEGFR-2 Inhibitor Sales by Country (2019-2030)
3.7.3 Latin America VEGFR-2 Inhibitor Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa VEGFR-2 Inhibitor Market Facts & Figures by Country
3.8.1 Middle East and Africa VEGFR-2 Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa VEGFR-2 Inhibitor Sales by Country (2019-2030)
3.8.3 Middle East and Africa VEGFR-2 Inhibitor Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global VEGFR-2 Inhibitor Sales by Type (2019-2030)
4.1.1 Global VEGFR-2 Inhibitor Sales by Type (2019-2024)
4.1.2 Global VEGFR-2 Inhibitor Sales by Type (2025-2030)
4.1.3 Global VEGFR-2 Inhibitor Sales Market Share by Type (2019-2030)
4.2 Global VEGFR-2 Inhibitor Revenue by Type (2019-2030)
4.2.1 Global VEGFR-2 Inhibitor Revenue by Type (2019-2024)
4.2.2 Global VEGFR-2 Inhibitor Revenue by Type (2025-2030)
4.2.3 Global VEGFR-2 Inhibitor Revenue Market Share by Type (2019-2030)
4.3 Global VEGFR-2 Inhibitor Price by Type (2019-2030)
5 Segment by Application
5.1 Global VEGFR-2 Inhibitor Sales by Application (2019-2030)
5.1.1 Global VEGFR-2 Inhibitor Sales by Application (2019-2024)
5.1.2 Global VEGFR-2 Inhibitor Sales by Application (2025-2030)
5.1.3 Global VEGFR-2 Inhibitor Sales Market Share by Application (2019-2030)
5.2 Global VEGFR-2 Inhibitor Revenue by Application (2019-2030)
5.2.1 Global VEGFR-2 Inhibitor Revenue by Application (2019-2024)
5.2.2 Global VEGFR-2 Inhibitor Revenue by Application (2025-2030)
5.2.3 Global VEGFR-2 Inhibitor Revenue Market Share by Application (2019-2030)
5.3 Global VEGFR-2 Inhibitor Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Company Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer VEGFR-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bayer VEGFR-2 Inhibitor Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Company Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer VEGFR-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pfizer VEGFR-2 Inhibitor Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Jiangsu Hengrui Pharmaceuticals
6.3.1 Jiangsu Hengrui Pharmaceuticals Company Information
6.3.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.3.3 Jiangsu Hengrui Pharmaceuticals VEGFR-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Jiangsu Hengrui Pharmaceuticals VEGFR-2 Inhibitor Product Portfolio
6.3.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.4 Chia Tai Tianqing
6.4.1 Chia Tai Tianqing Company Information
6.4.2 Chia Tai Tianqing Description and Business Overview
6.4.3 Chia Tai Tianqing VEGFR-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Chia Tai Tianqing VEGFR-2 Inhibitor Product Portfolio
6.4.5 Chia Tai Tianqing Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Company Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis VEGFR-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Novartis VEGFR-2 Inhibitor Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 AstraZeneca
6.6.1 AstraZeneca Company Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca VEGFR-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.6.4 AstraZeneca VEGFR-2 Inhibitor Product Portfolio
6.6.5 AstraZeneca Recent Developments/Updates
6.7 Exelixis
6.7.1 Exelixis Company Information
6.7.2 Exelixis Description and Business Overview
6.7.3 Exelixis VEGFR-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Exelixis VEGFR-2 Inhibitor Product Portfolio
6.7.5 Exelixis Recent Developments/Updates
6.8 Boehringer Ingelheim
6.8.1 Boehringer Ingelheim Company Information
6.8.2 Boehringer Ingelheim Description and Business Overview
6.8.3 Boehringer Ingelheim VEGFR-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Boehringer Ingelheim VEGFR-2 Inhibitor Product Portfolio
6.8.5 Boehringer Ingelheim Recent Developments/Updates
6.9 Eisai
6.9.1 Eisai Company Information
6.9.2 Eisai Description and Business Overview
6.9.3 Eisai VEGFR-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Eisai VEGFR-2 Inhibitor Product Portfolio
6.9.5 Eisai Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 VEGFR-2 Inhibitor Industry Chain Analysis
7.2 VEGFR-2 Inhibitor Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 VEGFR-2 Inhibitor Production Mode & Process
7.4 VEGFR-2 Inhibitor Sales and Marketing
7.4.1 VEGFR-2 Inhibitor Sales Channels
7.4.2 VEGFR-2 Inhibitor Distributors
7.5 VEGFR-2 Inhibitor Customers
8 VEGFR-2 Inhibitor Market Dynamics
8.1 VEGFR-2 Inhibitor Industry Trends
8.2 VEGFR-2 Inhibitor Market Drivers
8.3 VEGFR-2 Inhibitor Market Challenges
8.4 VEGFR-2 Inhibitor Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Bayer
Pfizer Inc
Jiangsu Hengrui Pharmaceuticals
Chia Tai Tianqing
Novartis
Astrazeneca plc
Exelixis Inc
Boehringer Ingelheim
Eisai Co Ltd
List of Tables
 Table 1. Global VEGFR-2 Inhibitor Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global VEGFR-2 Inhibitor Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global VEGFR-2 Inhibitor Market Competitive Situation by Manufacturers in 2023
 Table 4. Global VEGFR-2 Inhibitor Sales (K Units) of Key Manufacturers (2019-2024)
 Table 5. Global VEGFR-2 Inhibitor Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global VEGFR-2 Inhibitor Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global VEGFR-2 Inhibitor Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market VEGFR-2 Inhibitor Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of VEGFR-2 Inhibitor, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of VEGFR-2 Inhibitor, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of VEGFR-2 Inhibitor, Product Type & Application
 Table 12. Global Key Manufacturers of VEGFR-2 Inhibitor, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global VEGFR-2 Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VEGFR-2 Inhibitor as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global VEGFR-2 Inhibitor Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global VEGFR-2 Inhibitor Sales by Region (2019-2024) & (K Units)
 Table 18. Global VEGFR-2 Inhibitor Sales Market Share by Region (2019-2024)
 Table 19. Global VEGFR-2 Inhibitor Sales by Region (2025-2030) & (K Units)
 Table 20. Global VEGFR-2 Inhibitor Sales Market Share by Region (2025-2030)
 Table 21. Global VEGFR-2 Inhibitor Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global VEGFR-2 Inhibitor Revenue Market Share by Region (2019-2024)
 Table 23. Global VEGFR-2 Inhibitor Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global VEGFR-2 Inhibitor Revenue Market Share by Region (2025-2030)
 Table 25. North America VEGFR-2 Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America VEGFR-2 Inhibitor Sales by Country (2019-2024) & (K Units)
 Table 27. North America VEGFR-2 Inhibitor Sales by Country (2025-2030) & (K Units)
 Table 28. North America VEGFR-2 Inhibitor Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America VEGFR-2 Inhibitor Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe VEGFR-2 Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe VEGFR-2 Inhibitor Sales by Country (2019-2024) & (K Units)
 Table 32. Europe VEGFR-2 Inhibitor Sales by Country (2025-2030) & (K Units)
 Table 33. Europe VEGFR-2 Inhibitor Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe VEGFR-2 Inhibitor Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific VEGFR-2 Inhibitor Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific VEGFR-2 Inhibitor Sales by Region (2019-2024) & (K Units)
 Table 37. Asia Pacific VEGFR-2 Inhibitor Sales by Region (2025-2030) & (K Units)
 Table 38. Asia Pacific VEGFR-2 Inhibitor Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific VEGFR-2 Inhibitor Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America VEGFR-2 Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America VEGFR-2 Inhibitor Sales by Country (2019-2024) & (K Units)
 Table 42. Latin America VEGFR-2 Inhibitor Sales by Country (2025-2030) & (K Units)
 Table 43. Latin America VEGFR-2 Inhibitor Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America VEGFR-2 Inhibitor Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa VEGFR-2 Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa VEGFR-2 Inhibitor Sales by Country (2019-2024) & (K Units)
 Table 47. Middle East and Africa VEGFR-2 Inhibitor Sales by Country (2025-2030) & (K Units)
 Table 48. Middle East and Africa VEGFR-2 Inhibitor Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa VEGFR-2 Inhibitor Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global VEGFR-2 Inhibitor Sales (K Units) by Type (2019-2024)
 Table 51. Global VEGFR-2 Inhibitor Sales (K Units) by Type (2025-2030)
 Table 52. Global VEGFR-2 Inhibitor Sales Market Share by Type (2019-2024)
 Table 53. Global VEGFR-2 Inhibitor Sales Market Share by Type (2025-2030)
 Table 54. Global VEGFR-2 Inhibitor Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global VEGFR-2 Inhibitor Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global VEGFR-2 Inhibitor Revenue Market Share by Type (2019-2024)
 Table 57. Global VEGFR-2 Inhibitor Revenue Market Share by Type (2025-2030)
 Table 58. Global VEGFR-2 Inhibitor Price (US$/Unit) by Type (2019-2024)
 Table 59. Global VEGFR-2 Inhibitor Price (US$/Unit) by Type (2025-2030)
 Table 60. Global VEGFR-2 Inhibitor Sales (K Units) by Application (2019-2024)
 Table 61. Global VEGFR-2 Inhibitor Sales (K Units) by Application (2025-2030)
 Table 62. Global VEGFR-2 Inhibitor Sales Market Share by Application (2019-2024)
 Table 63. Global VEGFR-2 Inhibitor Sales Market Share by Application (2025-2030)
 Table 64. Global VEGFR-2 Inhibitor Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global VEGFR-2 Inhibitor Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global VEGFR-2 Inhibitor Revenue Market Share by Application (2019-2024)
 Table 67. Global VEGFR-2 Inhibitor Revenue Market Share by Application (2025-2030)
 Table 68. Global VEGFR-2 Inhibitor Price (US$/Unit) by Application (2019-2024)
 Table 69. Global VEGFR-2 Inhibitor Price (US$/Unit) by Application (2025-2030)
 Table 70. Bayer Company Information
 Table 71. Bayer Description and Business Overview
 Table 72. Bayer VEGFR-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. Bayer VEGFR-2 Inhibitor Product
 Table 74. Bayer Recent Developments/Updates
 Table 75. Pfizer Company Information
 Table 76. Pfizer Description and Business Overview
 Table 77. Pfizer VEGFR-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. Pfizer VEGFR-2 Inhibitor Product
 Table 79. Pfizer Recent Developments/Updates
 Table 80. Jiangsu Hengrui Pharmaceuticals Company Information
 Table 81. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
 Table 82. Jiangsu Hengrui Pharmaceuticals VEGFR-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. Jiangsu Hengrui Pharmaceuticals VEGFR-2 Inhibitor Product
 Table 84. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
 Table 85. Chia Tai Tianqing Company Information
 Table 86. Chia Tai Tianqing Description and Business Overview
 Table 87. Chia Tai Tianqing VEGFR-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 88. Chia Tai Tianqing VEGFR-2 Inhibitor Product
 Table 89. Chia Tai Tianqing Recent Developments/Updates
 Table 90. Novartis Company Information
 Table 91. Novartis Description and Business Overview
 Table 92. Novartis VEGFR-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 93. Novartis VEGFR-2 Inhibitor Product
 Table 94. Novartis Recent Developments/Updates
 Table 95. AstraZeneca Company Information
 Table 96. AstraZeneca Description and Business Overview
 Table 97. AstraZeneca VEGFR-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 98. AstraZeneca VEGFR-2 Inhibitor Product
 Table 99. AstraZeneca Recent Developments/Updates
 Table 100. Exelixis Company Information
 Table 101. Exelixis Description and Business Overview
 Table 102. Exelixis VEGFR-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 103. Exelixis VEGFR-2 Inhibitor Product
 Table 104. Exelixis Recent Developments/Updates
 Table 105. Boehringer Ingelheim Company Information
 Table 106. Boehringer Ingelheim Description and Business Overview
 Table 107. Boehringer Ingelheim VEGFR-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 108. Boehringer Ingelheim VEGFR-2 Inhibitor Product
 Table 109. Boehringer Ingelheim Recent Developments/Updates
 Table 110. Eisai Company Information
 Table 111. Eisai Description and Business Overview
 Table 112. Eisai VEGFR-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 113. Eisai VEGFR-2 Inhibitor Product
 Table 114. Eisai Recent Developments/Updates
 Table 115. Key Raw Materials Lists
 Table 116. Raw Materials Key Suppliers Lists
 Table 117. VEGFR-2 Inhibitor Distributors List
 Table 118. VEGFR-2 Inhibitor Customers List
 Table 119. VEGFR-2 Inhibitor Market Trends
 Table 120. VEGFR-2 Inhibitor Market Drivers
 Table 121. VEGFR-2 Inhibitor Market Challenges
 Table 122. VEGFR-2 Inhibitor Market Restraints
 Table 123. Research Programs/Design for This Report
 Table 124. Key Data Information from Secondary Sources
 Table 125. Key Data Information from Primary Sources
 Table 126. Authors List of This Report


List of Figures
 Figure 1. Product Picture of VEGFR-2 Inhibitor
 Figure 2. Global VEGFR-2 Inhibitor Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global VEGFR-2 Inhibitor Market Share by Type: 2023 & 2030
 Figure 4. Sorafenib Product Picture
 Figure 5. Sunitinib Product Picture
 Figure 6. Lenvatinib Product Picture
 Figure 7. Vandetanib Product Picture
 Figure 8. Cabozantinib Product Picture
 Figure 9. Nintedanib Product Picture
 Figure 10. Apatinib Product Picture
 Figure 11. Other Product Picture
 Figure 12. Global VEGFR-2 Inhibitor Market Value by Application (2024-2030) & (US$ Million)
 Figure 13. Global VEGFR-2 Inhibitor Market Share by Application: 2023 & 2030
 Figure 14. Cancer Therapy
 Figure 15. Ophthalmic Diseases
 Figure 16. Other
 Figure 17. Global VEGFR-2 Inhibitor Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 18. Global VEGFR-2 Inhibitor Market Size (2019-2030) & (US$ Million)
 Figure 19. Global VEGFR-2 Inhibitor Sales (2019-2030) & (K Units)
 Figure 20. Global VEGFR-2 Inhibitor Average Price (US$/Unit) & (2019-2030)
 Figure 21. VEGFR-2 Inhibitor Report Years Considered
 Figure 22. VEGFR-2 Inhibitor Sales Share by Manufacturers in 2023
 Figure 23. Global VEGFR-2 Inhibitor Revenue Share by Manufacturers in 2023
 Figure 24. Global 5 and 10 Largest VEGFR-2 Inhibitor Players: Market Share by Revenue in VEGFR-2 Inhibitor in 2023
 Figure 25. VEGFR-2 Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 26. Global VEGFR-2 Inhibitor Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 27. North America VEGFR-2 Inhibitor Sales Market Share by Country (2019-2030)
 Figure 28. North America VEGFR-2 Inhibitor Revenue Market Share by Country (2019-2030)
 Figure 29. United States VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. Canada VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. Europe VEGFR-2 Inhibitor Sales Market Share by Country (2019-2030)
 Figure 32. Europe VEGFR-2 Inhibitor Revenue Market Share by Country (2019-2030)
 Figure 33. Germany VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 34. France VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 35. U.K. VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 36. Italy VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. Russia VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. Asia Pacific VEGFR-2 Inhibitor Sales Market Share by Region (2019-2030)
 Figure 39. Asia Pacific VEGFR-2 Inhibitor Revenue Market Share by Region (2019-2030)
 Figure 40. China VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. Japan VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 42. South Korea VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 43. India VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 44. Australia VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. China Taiwan VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Southeast Asia VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 47. Latin America VEGFR-2 Inhibitor Sales Market Share by Country (2019-2030)
 Figure 48. Mexico VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 49. Brazil VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 50. Argentina VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. Colombia VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 52. Middle East and Africa VEGFR-2 Inhibitor Sales Market Share by Country (2019-2030)
 Figure 53. Middle East and Africa VEGFR-2 Inhibitor Revenue Market Share by Country (2019-2030)
 Figure 54. Turkey VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 55. Saudi Arabia VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 56. UAE VEGFR-2 Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 57. Global Sales Market Share of VEGFR-2 Inhibitor by Type (2019-2030)
 Figure 58. Global Revenue Market Share of VEGFR-2 Inhibitor by Type (2019-2030)
 Figure 59. Global VEGFR-2 Inhibitor Price (US$/Unit) by Type (2019-2030)
 Figure 60. Global Sales Market Share of VEGFR-2 Inhibitor by Application (2019-2030)
 Figure 61. Global Revenue Market Share of VEGFR-2 Inhibitor by Application (2019-2030)
 Figure 62. Global VEGFR-2 Inhibitor Price (US$/Unit) by Application (2019-2030)
 Figure 63. VEGFR-2 Inhibitor Value Chain
 Figure 64. VEGFR-2 Inhibitor Production Process
 Figure 65. Channels of Distribution (Direct Vs Distribution)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Global VEGF Inhibitors for Cancer Market Research Report 2024
Global VEGF Inhibitors Market Research Report 2024
Global Vascular Endothelial Growth Factor VEGF Inhibitors Market Insights Forecast to 2030
Global VEGF A Inhibitor Market Research Report 2024
Global Anti VEGF Therapy for Cancer Market Research Report 2024
VEGF Inhibitor Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anti VEGF Drugs for Angiogenesis related Disease Market Research Report 2024
Global Monoclonal Antibody VEGF Inhibitors Market Research Report 2024
Global Anti VEGF Ophthalmic Drugs Market Research Report 2024
Global Anti VEGF Therapeutic Market Research Report 2025
Global Anti VEGT Drugs Market Research Report 2024
Global Fusion Protein VEGF Inhibitor Market Research Report 2024
Global Anti Vascular Endothelial Growth Factor Therapeutic Market Research Report 2025
Global Single target Anti VEGF Drugs Market Research Report 2024
VEGF VEGFR Inhibitor Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Targeted Drug VEGFR2 Inhibitors for NSCLC Market Research Report 2024
Global Antiangiogenic Drugs Market Research Report 2024
Global Anti VEGF Ophthalmic Drug Market Research Report 2024
Global Angiogenesis Therapeutic Agent Market Research Report 2024
Global IL 2R Inhibitors Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions